Lenvatinib plus pembrolizumab demonstrated promising antitumor efficacy against recurrent endometrial cancer, which led to its FDA approval.
The development of aggressive lymphoma, typically DLBCL, in patients initially diagnosed with CLL is the defining characteristic of Richter transformation.
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
The researchers noted that medical distancing for those with cancer could help prevent the spread of the virus in this highly vulnerable population.
An analysis of previously approved novel anticancer agents estimates that more than 78% would have met the RACE for Children Act criteria for pediatric testing.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT.
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
More research is needed to define criteria for stopping therapy.
Work from home administrative staff may not have capabilities to obtain authorizations.
Cancer survivors aged 18 to 39 have consistently higher ‘very worried’ levels about retirement, bills.
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.